Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics (NQ: NKTR )

4.030 -0.130 (-3.12%)
Official Closing Price Updated: 4:15 PM EDT, Jun 24, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 24,401,986
Open 4.200
Bid (Size) 3.800 (2)
Ask (Size) 4.000 (16)
Prev. Close 4.160
Today's Range 3.980 - 4.260
52wk Range 3.020 - 19.37
Shares Outstanding 183,801,441
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Expert Ratings for Nektar Therapeutics
Within the last quarter, Nektar Therapeutics (NASDAQ:NKTR) has observed the following analyst ratings: 
Via Benzinga
Nektar Therapeutics's Return On Capital Employed Insights
According to Benzinga Pro data, during Q1, Nektar Therapeutics (NASDAQ:NKTR) posted sales of $24.82 million. Earnings were up 37.94%, but Nektar Therapeutics still reported an overall loss of $90.39... 
Via Benzinga

Performance

YTD
-70.50%
-70.50%
1 Month
+16.47%
+16.47%
3 Month
-27.39%
-27.39%
6 Month
-73.80%
-73.80%
1 Year
-76.66%
-76.66%

More News

Read More
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More
Via Benzinga
After Bristol Myers Cuts Ties, Nektar Implements Cost Restructuring
Via Benzinga
Expert Ratings for Nektar Therapeutics
Via Benzinga
The Daily Biotech Pulse - Tuesday, April,26
Via Talk Markets
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Nektar Therapeutics Shares Slide
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Mid-Day Market Update: U.S. Stocks Turn Lower; Bank of America Earnings Top Views
Via Benzinga
34 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Nektar Shares Are Down Almost 35%
Via Benzinga
Mid-Morning Market Update: Markets Open Higher; Dow Gains 100 Points
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 18, 2022
Via Benzinga
Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Best Performers Since 3/14 Pivot
Via Talk Markets
The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings
Via Benzinga
What 4 Analyst Ratings Have To Say About Nektar Therapeutics
Via Benzinga
Where Nektar Therapeutics Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.